Local wound infiltration with liposomal bupivacaine
decreases post-cesarean pain scores
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ABSTRACT & INTRODUCTION
METHODS
• Surgical patients are routinely prescribed opioid • Retrospective study of patients who underwent
analgesics that are strongly associated with drug
cesarean delivery from May-December 2019 at
overdose deaths.
Miami Valley Hospital in Dayton, OH
• Inclusion criteria: Age 18-45, BMI <60
•
Liposomal
bupivacaine
group
(n=57)
received
Legend
intraoperative liposomal bupivacaine in
0
addition to standard of care analgesics, which
\
includes intrathecal or epidural morphine
•
Control
group
(n=
59)
underwent
C
section
•• ,.. "';',..
(
,·,-.............within 1 week of LBG counterpart and within 3
•
• Liposomal bupivacaine is a long-acting local
weeks of gestational age of LBG counterpart
anesthetic that received FDA approval in 2011 for • Statistical analysis was completed using IBM
local surgical site infiltration to promote postSPSS Statistics
operative analgesia
PRIMARY OUTCOMES
• This anesthetic has demonstrated an
• Patient opiate use in morphine-equivalent
improvement in post-operative pain control in
doses (MED) from 24-48 hours postvarious surgical realms, indicating a decreased
operatively
need for opiates and subsequently decreased
• Patient pain ratings via 11-point Likert Scale
risks. However, few studies have investigated its
averaged every 12 hours
use at the time of cesarean delivery.
Number and age-adjusted rates of drug overdose deaths by state, US 2018
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Patients who received liposomal bupivacaine
during C-section had significantly lower pain
scores 0-24 hours after surgery.
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CONCLUSIONS & FUTURE DIRECTIONS
• Confounding factors include differences between
post-operative opiate pain medication
administration by nursing care which could lead
to lack of significant differences in opiate use.
• Future directions include a prospective
randomized control trial emphasizing patient and
healthcare worker education on post-operative
analgesic usage. Additional studies should
assess differences between liposomal and
systemic bupivacaine
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